Embecta Corp. (Nasdaq: EMBC), a leader in diabetes care technology, has announced a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based innovator in medical devices and drug-delivery technologies, in a transaction valued at up to £150 million. The agreement includes an upfront cash payment of £100 million at closing, with an additional £50 million contingent upon achieving specific commercial milestones related to the Aidaptus® auto-injector platform by the end of 2028. This acquisition, unanimously approved by Embecta's Board of Directors, is expected to close in the fiscal third quarter of 2026, subject to regulatory approvals and customary closing conditions. Owen Mumford's expertise in drug delivery systems and established relationships with major pharmaceutical companies will enhance Embecta's portfolio and accelerate its transformation into a broad-based medical supplies company. The acquisition is anticipated to contribute positively to Embecta's revenue growth trajectory, with expectations of high-single-digit returns on invested capital by year four. The strategic move positions Embecta to capitalize on the expanding market for drug-delivery devices, supporting both generic and branded therapies. The transaction is seen as a significant step in Embecta's strategy to broaden its product offerings and enhance its operational capabilities in the medical supplies sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.